Potent C5a receptor antagonist (IC50
= 20 nM). Also MrgX2 agonist. Stimulates MrgX2-mediated mast cell degranulation. Also inhibits C5a-induced hypernociception in rats, inhibits lung metastasis in a mouse breast cancer model and reduces atherosclerotic lesions in a mouse model of atherosclerosis.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Other Product-Specific Information:
Role of complement C5a in mechanical inflammatory hypernociception: potential use of C5a receptor antagonists to control inflammatory pain.
Ting et al.
PMX-53 as a dual CD88 antagonist and an agonist for Mas-related gene 2 (MrgX2) in human mast cells.
Subramanian et al.
Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a.
Finch et al.
Complement c5a receptor facilitates cancer metastasis by altering T-cell responses in the metastatic niche.
Vadrevu et al.
Cancer Res., 2014;74:3454
Complement C5a inhibition reduces atherosclerosis in ApoE-/- mice.
Manthey et al.
FASEB J, 2011;25:2447